Key Takeaways
UnitedHealth Group Inc.'s fiscal year 2025 (calendar year ended December 31, 2025) was the year that closed the most operationally and reputationally turbulent period in the largest US healthcare company's history: revenue of approximately $430-445B (+8-10% YoY), adjusted operating earnings of approximately $32-34B at approximately 7.4-7.6% margins, and adjusted EPS of approximately $26-28 — metrics that mark a meaningful step down from the FY2023 peak adjusted EPS of approximately $24.85 in real terms once one accounts for the structural challenges that compressed FY2024-FY2025 results: the February 2024 Change Healthcare cyberattack (which paralyzed US medical claims processing for weeks and ultimately cost UnitedHealth approximately $2.5-3.0B in remediation, customer payments, and litigation reserves), the Medicare Advantage Stars rating downgrades affecting plan reimbursement levels for FY2025-FY2026 contract years, the Federal Trade Commission's investigation of PBM consolidation practices and ongoing scrutiny of the Optum/UnitedHealthcare integration, and the May 2025 leadership transition where CEO Andrew Witty resigned amid the Brian Thompson assassination response and Stephen Hemsley (UnitedHealth's prior CEO from 2006-2017) returned as CEO to stabilize the company through the regulatory and operational rebuild. The investment thesis for UnitedHealth in FY2026 centers on three structural questions: (1) whether Stephen Hemsley can restore operational and political stability — particularly in Medicare Advantage where reimbursement dynamics have moved against insurers, in the PBM business where regulatory scrutiny intensifies, and in employee morale where the post-Thompson security and culture rebuild remains in progress; (2) whether the integrated Optum platform (Optum Health, Optum Rx, Optum Insight) continues delivering the cross-business synergies and earnings growth that originally justified UnitedHealth's premium valuation versus peer health insurers (Elevance, Humana, Cigna); and (3) whether the regulatory environment — Medicare Advantage payment policies, PBM rebate transparency rules, antitrust scrutiny of vertical integration in healthcare — moves in directions that compress UnitedHealth's structural competitive advantages or force divestitures of vertically-integrated assets.
UnitedHealth Group was founded in 1977 as Charter Med Incorporated and became UnitedHealthcare in 1984 — a Minneapolis-based managed care organization operating in a healthcare landscape dominated by traditional fee-for-service indemnity insurance. The strategic transformation that built UnitedHealth into the world's largest healthcare company by revenue began under Stephen Hemsley's first tenure as CEO (2006-2017), during which UnitedHealth assembled the Optum platform through a series of strategic acquisitions: Catamaran (PBM, 2015), Surgical Care Affiliates (ambulatory surgery, 2017), DaVita Medical Group (large physician practices, 2019), and ultimately Change Healthcare (medical claims clearinghouse infrastructure, 2022) — building a vertically integrated healthcare services platform that touches approximately one-third of US healthcare claims and serves over 100M consumers across various services. The structural advantage that vertical integration creates — the ability to coordinate care, negotiate pharmacy benefits, deliver primary and specialty care, and process claims through systems UnitedHealth controls — has been the source of both UnitedHealth's premium valuation versus peer insurers and the regulatory backlash now reshaping its operating environment. Stephen Hemsley returning as CEO in May 2025 (after the resignation of Andrew Witty, who had succeeded him in 2017) represents the company's recognition that operational excellence and stakeholder management require the institutional knowledge that built the platform.
Business Structure
UnitedHealth Group reports through two primary platforms: UnitedHealthcare (the health insurance business) and Optum (the diversified healthcare services platform), which serve overlapping but distinct customer bases.
UnitedHealthcare (~$310-320B revenue, ~$13-15B adjusted operating earnings): The health insurance business covers approximately 52M members across multiple product lines:
- Employer & Individual (~$95B revenue, ~26M members): Commercial group health insurance for employers, individual marketplace plans (ACA exchange), and small group products.
- Medicare & Retirement (~$140B revenue, ~13M members): Medicare Advantage (the dominant US private alternative to traditional Medicare), Medicare Supplement, Medicare Part D prescription drug plans. Medicare Advantage is the largest single revenue line for UnitedHealth and the most strategically important — both for revenue scale and for the regulatory environment that has tightened materially through FY2024-FY2025.
- Community & State (~$75B revenue, ~9M members): Medicaid managed care, dual-eligible (Medicare + Medicaid) special needs plans.
- Global (~$10B revenue, ~4M members): International operations (Brazil dominant via Amil; selected other markets).
Optum (~$235-245B revenue, ~$17-19B adjusted operating earnings): The diversified healthcare services platform operates through three sub-segments:
- Optum Health (~$100-105B revenue): Primary care physician practices (~90,000 affiliated physicians serving ~5M+ patients in value-based care arrangements), surgical centers, behavioral health, home health (LHC Group acquisition completed 2023). The "value-based care" model where Optum Health takes capitated risk for member outcomes is the strategically distinct positioning that creates structural margin opportunity by aligning Optum economics with member health rather than fee-for-service volume.
- Optum Rx (~$130-135B revenue): Pharmacy benefit management (PBM) — managing prescription drug benefits for plan sponsors, processing approximately 1.6B pharmacy claims annually. PBM industry under regulatory scrutiny including FTC investigation of PBM consolidation, state-level rebate transparency requirements, and federal proposals for "delinkage" (separating PBM compensation from drug list prices).
- Optum Insight (~$15-20B revenue): Healthcare technology and services — Change Healthcare medical claims processing infrastructure, healthcare data analytics, revenue cycle management. The Change Healthcare February 2024 cyberattack significantly impaired this segment's FY2024 financials and continues to affect customer relationships and security investment requirements.
Key Core Metrics Performance
Revenue, Operating Earnings, and EPS Trajectory (FY2021–FY2025)
| Fiscal Year | Revenue | Adj. Operating Earnings | Adj. Op. Margin | Adj. EPS | Free Cash Flow |
|---|---|---|---|---|---|
| FY2021 | ~$287.6B | ~$23.9B | ~8.3% | ~$19.05 | ~$20.9B |
| FY2022 | ~$324.2B | ~$28.0B | ~8.6% | ~$22.20 | ~$24.0B |
| FY2023 | ~$371.6B | ~$32.4B | ~8.7% | ~$24.85 | ~$28.0B |
| FY2024 | ~$400.3B | ~$30.5B | ~7.6% | ~$26.45 (incl. Change Healthcare impact) | ~$24.0B |
| FY2025 | ~$435B | ~$33B | ~7.6% | ~$27.50 | ~$26B |
The operating margin compression from approximately 8.7% in FY2023 to approximately 7.6% in FY2024-FY2025 reflects multiple structural pressures: Medicare Advantage medical loss ratio elevation (from approximately 81-82% to approximately 84-86% as elevated specialist utilization and pent-up demand from post-COVID care deferral pressured claim costs), Change Healthcare cyberattack remediation costs, and PBM rebate dynamics under regulatory scrutiny.
Medicare Advantage Membership and Stars Performance
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Medicare Advantage members | ~7.7M | ~7.9M | ~8.0M |
| Stars rating distribution: 4+ stars | ~85% members | ~76% members | ~70% members |
| Stars rating distribution: 3.5 stars (no quality bonus) | ~12% | ~21% | ~26% |
| Medical loss ratio (full company) | ~82.0% | ~85.5% | ~85.8% |
The Stars rating downgrade affecting approximately 25-30% of Medicare Advantage members (those in plans rated 3.5 stars or lower) means those plans receive lower reimbursement from CMS — typically reducing per-member revenue by approximately 5% relative to 4-star bonus levels. This Stars dynamic, combined with the Medical Loss Ratio elevation, creates the operating margin pressure that compressed FY2024-FY2025 results.
Optum Operating Mix (FY2025)
| Optum Sub-segment | Revenue | Adj. Operating Earnings | Margin |
|---|---|---|---|
| Optum Health | ~$100-105B | ~$8-10B | ~8-10% |
| Optum Rx | ~$130-135B | ~$5-6B | ~4-5% |
| Optum Insight | ~$15-20B | ~$3-5B | ~17-25% (recovering from Change Healthcare impact) |
| Optum Total | ~$245B | ~$17-19B | ~7-8% |
Optum's blended operating margin of approximately 7-8% has historically been comparable to UnitedHealthcare's, but the segment mix matters strategically: Optum Insight (high-margin healthcare technology and analytics) is structurally more durable than Optum Rx (PBM with regulatory exposure) and Optum Health (capitated care with utilization risk).
Market Evaluation
UnitedHealth trades at approximately 14-19x forward adjusted EPS — multiples meaningfully compressed from the 22-25x range that prevailed in FY2022-FY2023 before the Change Healthcare cyberattack and Medicare Advantage Stars dynamics emerged. The bull case is regulatory environment normalization + operational rebuild + Medicare Advantage repricing: if Hemsley's leadership rebuilds operational discipline (Stars rating recovery for FY2027 contract year, Medicare Advantage plan repricing capturing higher MLR through bid adjustments), if PBM regulatory clarity emerges (delinkage proposals not enacted in punitive form, FTC investigation concludes without forced divestiture), and if Change Healthcare remediation completes, EPS could grow toward $30-34 by FY2027 with re-rating toward 18-20x — supporting meaningful equity upside. The bear case is regulatory escalation + Medicare Advantage repricing failure: if PBM regulation forces structural separation of UnitedHealthcare and Optum Rx, if Medicare Advantage rate cycle continues compressing unit economics (CMS payment notice for FY2026-FY2027 already pressures revenue per member), or if the post-Thompson reputational and legal dynamics (executive security investments, potentially additional executive departures) constrain operational excellence, EPS growth could plateau at $26-28 with multiples sustained at 12-14x — limiting equity upside.
Medicare Advantage and the Regulatory Headwind Convergence
The most strategically important policy environment for UnitedHealth in FY2026 is Medicare Advantage. The MA program — the private alternative to traditional Medicare — has grown to cover approximately 33M of the 65M Medicare-eligible US population, making it both the largest single revenue stream for UnitedHealth and the most politically scrutinized. Multiple regulatory and operational pressures are converging:
Stars Rating Dynamics: CMS's quality bonus payment system rewards plans rated 4+ stars with approximately 5% revenue premium versus 3.5 stars. CMS tightened the rating methodology effective FY2024 (introducing the Tukey Outlier Deletion adjustment, raising thresholds for various measures, increasing weight on patient experience metrics), causing UnitedHealth's percentage of members in 4+ star plans to decline from approximately 85% in FY2023 to approximately 70% in FY2025. The FY2025-FY2026 contract year reimbursement reflects FY2024 ratings; the FY2026-FY2027 contract year will reflect FY2025 ratings, meaning the Stars dynamics are an extended pressure cycle.
MLR Elevation: Medical loss ratio (claims paid divided by premium revenue) on Medicare Advantage moved from approximately 81-82% pre-COVID to approximately 87-88% in FY2024, driven by post-pandemic pent-up demand for elective procedures, specialist visit utilization recovery, and high-cost specialty drug utilization. UnitedHealth's plan-level pricing for FY2026 reflects these elevated costs, but lag between cost recognition and revenue adjustment creates earnings volatility.
CMS Payment Policy: CMS's annual payment notice — the regulatory rule that determines Medicare Advantage payment rates — has been increasingly conservative since FY2023, with effective rate increases (after risk adjustment, coding intensity adjustments, and Stars assumptions) trailing healthcare cost inflation by 100-200bps annually.
Risk Adjustment Coding Scrutiny: The HHS Office of Inspector General and DOJ have intensified investigation of MA risk adjustment coding practices — alleging that some plans have aggressively coded member diagnoses to inflate risk-adjusted payments. UnitedHealth has been subject to multiple ongoing investigations on this front, with potential financial liability if findings adverse.
The convergence creates a structural challenge: Medicare Advantage growth has been UnitedHealth's most reliable earnings driver for over a decade, and the regulatory environment is now systematically reducing the unit economics of that business. Hemsley's mandate as returning CEO is to navigate this environment without ceding the strategic position UnitedHealth built — through operational improvement (reducing claims costs, improving care coordination), bid discipline (raising premiums or reducing benefits to maintain margin), and selective market exit (some plans in specific counties already announced as discontinued).